Literature DB >> 33128792

Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.

Bernhard Kratzer1, Doris Trapin1, Paul Ettel1, Ulrike Körmöczi1, Arno Rottal1, Friedrich Tuppy1, Melanie Feichter1, Pia Gattinger2, Kristina Borochova2, Yulia Dorofeeva2, Inna Tulaeva2,3, Milena Weber2, Katharina Grabmeier-Pfistershammer1, Peter A Tauber1, Marika Gerdov4, Bernhard Mühl5, Thomas Perkmann4, Ingrid Fae6, Sabine Wenda6, Harald Führer7, Rainer Henning8, Rudolf Valenta2,3,9,10, Winfried F Pickl1.   

Abstract

BACKGROUND: SARS-CoV-2 has triggered a pandemic that is now claiming many lives. Several studies have investigated cellular immune responses in COVID-19-infected patients during disease but little is known regarding a possible protracted impact of COVID-19 on the adaptive and innate immune system in COVID-19 convalescent patients.
METHODS: We used multiparametric flow cytometry to analyze whole peripheral blood samples and determined SARS-CoV-2-specific antibody levels against the S-protein, its RBD-subunit, and viral nucleocapsid in a cohort of COVID-19 convalescent patients who had mild disease ~10 weeks after infection (n = 109) and healthy control subjects (n = 98). Furthermore, we correlated immunological changes with clinical and demographic parameters.
RESULTS: Even ten weeks after disease COVID-19 convalescent patients had fewer neutrophils, while their cytotoxic CD8+ T cells were activated, reflected as higher HLA-DR and CD38 expression. Multiparametric regression analyses showed that in COVID-19-infected patients both CD3+ CD4+ and CD3+ CD8+ effector memory cells were higher, while CD25+ Foxp3+ T regulatory cells were lower. In addition, both transitional B cell and plasmablast levels were significantly elevated in COVID-19-infected patients. Fever (duration, level) correlated with numbers of central memory CD4+ T cells and anti-S and anti-RBD, but not anti-NC antibody levels. Moreover, a "young immunological age" as determined by numbers of CD3+ CD45RA+ CD62L+ CD31+ recent thymic emigrants was associated with a loss of sense of taste and/or smell.
CONCLUSION: Acute SARS-CoV-2 infection leaves protracted beneficial (ie, activation of T cells) and potentially harmful (ie, reduction of neutrophils) imprints in the cellular immune system in addition to induction of specific antibody responses.
© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  B cells; SARS-CoV-2; T cells; clinical immunology; coronavirus disease 2019; flow cytometry; infections; lymphocytes

Year:  2020        PMID: 33128792     DOI: 10.1111/all.14647

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  27 in total

Review 1.  Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.

Authors:  Clara Di Vito; Francesca Calcaterra; Nicolò Coianiz; Sara Terzoli; Antonio Voza; Joanna Mikulak; Silvia Della Bella; Domenico Mavilio
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection.

Authors:  Milena Wiech; Piotr Chroscicki; Julian Swatler; Dawid Stepnik; Sara De Biasi; Michal Hampel; Marta Brewinska-Olchowik; Anna Maliszewska; Katarzyna Sklinda; Marek Durlik; Waldemar Wierzba; Andrea Cossarizza; Katarzyna Piwocka
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

3.  Serum levels of the IgA isotype switch factor TGF-β1 are elevated in patients with COVID-19.

Authors:  Er-Yi Wang; Hao Chen; Bao-Qing Sun; Hui Wang; Hui-Qi Qu; Yichuan Liu; Xi-Zhuo Sun; Jingchun Qu; Zhang-Fu Fang; Lifeng Tian; Yi-Feng Zeng; Shau-Ku Huang; Hakon Hakonarson; Zhi-Gang Liu
Journal:  FEBS Lett       Date:  2021-05-21       Impact factor: 3.864

Review 4.  [Systemic consequences and clinical aspects of SARS-CoV-2 infection].

Authors:  Sigurd F Lax; Kristijan Skok; Peter M Zechner; Lisa Setaffy; Harald H Kessler; Norbert Kaufmann; Klaus Vander; Natalija Cokić; Urša Maierhofer; Ute Bargfrieder; Michael Trauner
Journal:  Pathologe       Date:  2021-02-11       Impact factor: 1.011

5.  Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19.

Authors:  Maxim Shkurnikov; Stepan Nersisyan; Tatjana Jankevic; Alexei Galatenko; Ivan Gordeev; Valery Vechorko; Alexander Tonevitsky
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

Review 6.  The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment.

Authors:  Yifei Wang; Jingbin Zheng; Md Sahidul Islam; Yang Yang; Yuanjia Hu; Xin Chen
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

Review 7.  How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn.

Authors:  Cinzia Signorini; Patrizia Pignatti; Teresa Coccini
Journal:  Life (Basel)       Date:  2021-02-25

8.  Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.

Authors:  Feargal J Ryan; Christopher M Hope; Makutiro G Masavuli; Miriam A Lynn; Simon C Barry; Branka Grubor-Bauk; David J Lynn; Zelalem A Mekonnen; Arthur Eng Lip Yeow; Pablo Garcia-Valtanen; Zahraa Al-Delfi; Jason Gummow; Catherine Ferguson; Stephanie O'Connor; Benjamin A J Reddi; Pravin Hissaria; David Shaw; Chuan Kok-Lim; Jonathan M Gleadle; Michael R Beard
Journal:  BMC Med       Date:  2022-01-14       Impact factor: 8.775

9.  Early Response of CD8+ T Cells in COVID-19 Patients.

Authors:  Deni Ramljak; Martina Vukoja; Marina Curlin; Katarina Vukojevic; Maja Barbaric; Una Glamoclija; Bejana Purisevic; Olivera Peric; Violeta Soljic
Journal:  J Pers Med       Date:  2021-12-03

Review 10.  Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic-Experience and Outlines.

Authors:  Monica Neagu; Carolina Constantin; Mihaela Surcel
Journal:  Int J Environ Res Public Health       Date:  2021-12-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.